scholarly journals Proliferative Dermal Lesion in Congenital Nevus

2020 ◽  
Author(s):  
Keyword(s):  
Congenital Nevus ◽  
Dermal Lesion

Halo congenital nevus

1977 ◽  
Vol 113 (11) ◽  
pp. 1572-1575 ◽  
Author(s):  
M. H. Brownstein
Keyword(s):  
Congenital Nevus

Heterochromia of congenital nevus of abdomen

1968 ◽  
Vol 98 (1) ◽  
pp. 94-95
Author(s):  
R. C. Gibbs
Keyword(s):  
Congenital Nevus

Minimal deviation melanoma with epidermotropic metastases arising in a congenital nevus

1980 ◽  
Vol 4 (2) ◽  
pp. 175-183 ◽  
Author(s):  
Thomas F.C.S. Warner ◽  
In Sook Seo ◽  
James E. Bennett
Keyword(s):  
Congenital Nevus ◽  
Minimal Deviation

Sclerotic Regressing Large Congenital Nevus

2016 ◽  
Vol 33 (6) ◽  
pp. e366-e367 ◽  
Author(s):  
Aikaterini Patsatsi ◽  
Miltiadis Kokolios ◽  
Olga Pikou ◽  
Vasilios Lambropoulos ◽  
Ioannis Efstratiou ◽  
...  
Keyword(s):  
Congenital Nevus

Detection of a multilineage mosaic NRAS mutation c.181C>A (p.Gln61Lys) in an individual with a complex congenital nevus syndrome

2018 ◽  
Vol 32 (3) ◽  
pp. 470-473
Author(s):  
Maximilian Ulrich ◽  
Sigrid Tinschert ◽  
Eberhard Siebert ◽  
Ingolf Franke ◽  
Thomas Tüting ◽  
...  
Keyword(s):  
Nras Mutation ◽  
Congenital Nevus

Impressive Pseudotumoral Proliferative Nodules in a Giant Congenital Nevus of a Newborn

2012 ◽  
Vol 30 (3) ◽  
pp. e5-e7 ◽  
Author(s):  
Giancarlo Palmieri ◽  
Maria Francesca Bianciardi Valassina ◽  
Giorgio Proia ◽  
May El Hachem ◽  
Francesco Callea ◽  
...  
Keyword(s):  
Congenital Nevus ◽  
Giant Congenital Nevus

Subungual Congenital Nevus with Recurrent Nevus Phenomenon

2015 ◽  
Vol 32 (5) ◽  
pp. e197-e199 ◽  
Author(s):  
Rami H. El-Khayat ◽  
Abid Rashid ◽  
Maureen Y. Walsh ◽  
Kevin E. McKenna
Keyword(s):  
Congenital Nevus ◽  
Recurrent Nevus

scholarly journals Efficacy of Tecovirimat (ST-246) in Nonhuman Primates Infected with Variola Virus (Smallpox)

2013 ◽  
Vol 57 (12) ◽  
pp. 6246-6253 ◽  
Author(s):  
Eric M. Mucker ◽  
Arthur J. Goff ◽  
Joshua D. Shamblin ◽  
Douglas W. Grosenbach ◽  
Inger K. Damon ◽  
...  
Keyword(s):  
Nonhuman Primates ◽  
Pharmacokinetic Profile ◽  
Therapeutic Benefit ◽  
World Health ◽  
Smallpox Vaccination ◽  
Oral Drug ◽  
Variola Virus ◽  
Content Type ◽  
Virus Shedding ◽  
Dermal Lesion

ABSTRACTNaturally occurring smallpox has been eradicated but remains a considerable threat as a biowarfare/bioterrorist weapon (F. Fleck, Bull. World Health Organ.81:917–918, 2003). While effective, the smallpox vaccine is currently not recommended for routine use in the general public due to safety concerns (http://www.bt.cdc.gov/agent/smallpox/vaccination). Safe and effective countermeasures, particularly those effective after exposure to smallpox, are needed. Currently, SIGA Technologies is developing the small-molecule oral drug, tecovirimat (previously known as ST-246), as a postexposure therapeutic treatment of orthopoxvirus disease, including smallpox. Tecovirimat has been shown to be efficacious in preventing lethal orthopoxviral disease in numerous animal models (G. Yang, D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, et al., J. Virol.79:13139–13149, 2005; D. C. Quenelle, R. M. Buller, S. Parker, K. A. Keith, D. E. Hruby, et al., Antimicrob. Agents Chemother.,51:689–695, 2007; E. Sbrana, R. Jordan, D. E. Hruby, R. I. Mateo, S. Y. Xiao, et al., Am. J. Trop. Med. Hyg.76:768–773, 2007). Furthermore, in clinical trials thus far, the drug appears to be safe, with a good pharmacokinetic profile. In this study, the efficacy of tecovirimat was evaluated in both a prelesional and postlesional setting in nonhuman primates challenged intravenously with 1 × 108PFU ofVariola virus(VARV; the causative agent of smallpox), a model for smallpox disease in humans. Following challenge, 50% of placebo-treated controls succumbed to infection, while all tecovirimat-treated animals survived regardless of whether treatment was started at 2 or 4 days postinfection. In addition, tecovirimat treatment resulted in dramatic reductions in dermal lesion counts, oropharyngeal virus shedding, and viral DNA circulating in the blood. Although clinical disease was evident in tecovirimat-treated animals, it was generally very mild and appeared to resolve earlier than in placebo-treated controls that survived infection. Tecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox-infected humans.

Sign in / Sign up

Export Citation Format

Share Document